After recently taking profit in the CURE ETF, we again add the name back onto our watchlist and identify the range where we expect buying support to rebuild.
Buy $58.50 target.
You're not a member! Trial today
Separate to the above opportunity, we see upside in the large-cap biotech stocks in the US. In particular, we like Abbvie, Biogen, Gilead, Johnson & Johnson, Merk, and Pfizer.
If you’d like to discuss setting up a US broking account with Investor Signals, please call me on 1300 614 002.
Since writing the above post CURE has rallied 5% and the large-cap biotech names were among the best performers overnight in the US.
Biogen rallied 44% overnight. This is a holding in our US high conviction portfolio.
